Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Inotuzumab Ozogamicin (INO) Combined to Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor Acute Lymphoblastic Leukemia

NCT03249870 is registered in ClinicalTrials.gov with Versailles Hospital as lead sponsor.

NCT NCT03249870
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03249870 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Inotuzumab Ozogamicin (INO) Combined to Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor Acute Lymphoblastic Leukemia
Lead sponsor
Versailles Hospital
Phase
Phase 2
Overall status
Completed
Start date
December 28, 2017
Completion date
October 17, 2024
Enrollment
131 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia (all) - philadelphia chromosome (ph)-negative cd22+ b-cell precursor (bcp)